More Videos
|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Social Networking's 'Naked' Truth
- Geek Squad V. Gizmodo
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- WPP's Sir Martin Sorrell on the Ad Recession
- Four Things You Should Be Doing Now To Break Out
- Proprietary Trading May Cause October Crash: Investor
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
RSS FEED
Text Size 
 |
AP Pfizer's Viagra |
A few months ago, during the last earnings season, I put forth an anecdotal theory (see links below) that the weak economy may be leading to flacid sales of the expensive pills for erectile dysfunction (ED). But this earnings season's results show that impotence drug sales may be more resilient than I thought.
Earlier this week Pfizer [PFE
Loading...
()
]reported that Viagra sales went up 13 percent from the third quarter of last year to the third quarter of this year. Not only that, but U.S. revenue from the little blue pill climbed sequentially (from the second quarter of this year to the third quarter) from $199 million to $236 million. That's not all new business, much of the increase probably comes from a price increase, but even that flies in the face of a report in "The New York Times" yesterday about people giving up or cutting back on their meds in this economy. Even though docs and the companies will tell you impotence could be a symptom of serious medical problems, ED drugs are considered so-called lifestyle, elective products. So, the fact that guys are paying even more for them these days may say something.
Then, this morning Eli Lilly [LLY
Loading...
()
]reported that U.S. revenue from Cialis jumped 20 percent quarter over quarter. And they rose $12 million sequentially. Here, too, on the conference call officials acknowledged most of that comes from a price hike and not so much from more demand. They also said Cialis' market share inched up 1.4 percent in the quarter in part due to the recent launch of a one-a-day version of the drug. And for those who think direct-to-consumer advertising doesn't work, LLY said since it started running commercials for one-a-day Cialis that its market share bumped up another .06 percent. Even sales of little Levitra co-owned by GlaxoSmithKline[GSK
Loading...
()
], Schering-Plough [SGP
Loading...
()
]and Bayer [BAY
Loading...
()
]crept up ever so slightly. Maybe it's all part of the whole cocooning, stay-at-home, go out less thing.
Viva Viagra, indeed.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes